JCHOR
Journal of Current Hematology & Oncology Research

The Journal of Current Hematology & Oncology Research regularly publishes internationally qualified research in hematology and oncology within the current scholarly knowledge.

ISSN: Active
eISSN: 2980-0854
Creative Commons CC BY-NC-ND 4.0 International License.
EndNote Style

Online Manuscript System

Index
Case Report
A rare case report: cytarabine-induced skin rash
Abstract
Diffuse Large B-Cell Lymphoma (DLBCL) is the most common subtype of Non-Hodgkin Lymphoma (NHL). The standard first-line treatment for DLBCL is the R-CHOP protocol. For relapsed or refractory cases, salvage regimens such as R-ICE, R-DHAP, or MATRIX are utilized. Cytarabine, a commonly used antimetabolite in hematologic malignancies, has various side effects, including dermatological toxicity. A 61-year-old male with DLBCL received six cycles of R-CHOP chemotherapy and was considered in remission. However, he presented with neurological symptoms, and imaging confirmed CNS relapse. The patient was started on the MATRIX regimen, including high-dose cytarabine. On the third day of treatment, he developed a palmar rash, which later progressed to petechiae and purpura on the trunk, back, and lower extremities. No systemic corticosteroid treatment was administered, and the rash gradually resolved by the 13th day. Cytarabine-induced skin reactions, such as palmar-plantar erythrodysesthesia, morbilliform rashes, and acute generalized exanthematous pustulosis, have been reported. However, cases involving petechiae and purpura are rare. These reactions are usually self-limiting and do not require systemic intervention. The severity of cytarabine-induced dermatologic toxicity may be dose-dependent, with repeated doses showing reduced severity. In this case, the patient exhibited a cutaneous reaction without systemic involvement, supporting the benign nature of cytarabine-related skin toxicity. This case highlights a rare dermatological reaction to cytarabine during the MATRIX regimen in a DLBCL patient with CNS relapse. Although cytarabine-induced skin toxicity is uncommon, clinicians should be aware of its potential manifestations and manage patients symptomatically to avoid unnecessary interventions while ensuring treatment continuation.

Keywords : Chemotherapy, cytarabine, palmar-plantar erythema, generalized exanthematous pustulosis

Download Article


1. Cetkovská P, Pizinger K, Cetkovský P. High-dose cytosine arabinoside-induced cutaneous reactions. J Eur Acad Dermatol Venereol. 2002;16(5): 481-485. doi:10.1046/j.1468-3083.2002.00395
2. Republic of Turkey, Ministry of Health. 2014 Health Statistics Yearbook. Ministry of Health Publications; 2014.
3. Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood. 2006;107(1):265-276. doi:10.1182/blood-2005- 06-2508
4. Ozkan A, Apak H, Celkan T, Yüksel L, Yildiz I. Toxic epidermal necrolysis after the use of high-dose cytosine arabinoside. Pediatr Dermatol. 2001;18(1):38-40. doi:10.1046/j.1525-1470.2001.018001038
5. Zhang B, Bolognia J, Marks P, Podoltsev N. Enhanced skin toxicity associated with the combination of clofarabine plus cytarabine for the treatment of acute leukemia. Cancer Chemother Pharmacol. 2014;74(2): 303-307. doi:10.1007/s00280-014-2504-y
6. Waseem H, Henriquez Felipe C, Hashmi AT, et al. Isolated bilateral ear and scalp rash after cytarabine therapy for acute myelogenous leukemia: a report and literature review. Am J Ther. 2019;26(5):e653-e655. doi:10. 1097/MJT.0000000000000850
7. Brandt K, Schäkel K, Stölzel F, Janschek J, Ehninger G, Schaich M. Auricular oedema and dyshidrotic eczema in a patient with acute myeloid leukaemia treated with cytarabine. Case Rep Oncol. 2010;3(3): 349-353. doi:10.1159/000321367
8. Karol SE, Yang W, Smith C, et al. Palmar-plantar erythrodysesthesia syndrome following treatment with high-dose methotrexate or high-dose cytarabine. Cancer. 2017;123(18):3602-3608. doi:10.1002/cncr.307
Article available in :
Volume 3, Issue 3, 2025
Page : 74-76
https://doi.org/10.51271/JCHOR-0066
Article Information
Received : 12 Mar 2025
Accepted : 09 Nis 2025
Published : 08 Ağu 2025
Corresponding Author :

Melis Gül Gülsar Çaycı: Department of Internal Medicine, Faculty of Medicine, Necmettin Erbakan University, Konya, Turkiye

[email protected]
Citation : Gülsar Çaycı MG, Satılmış O, Demircioğlu S, Tekinalp A. A rare case report: cytarabine-induced skin rash. J Curr Hematol Oncol Res. 2025;3(3):74-76.

Read: 40
Download : 254
Cited: 0
_Footer